Health Catalyst, which provides data and analytics tech to healthcare organizations, raises $182M in its IPO, closing up 51% at $39.17 and now valued at ~$1.6B
Wall Street Journal : Tweets: @wsj and @bryce Tweets: @wsj : Health-technology firms Livongo and Health Catalyst both priced their IPOs above their already-boosted projections and sold more stock than originally expected https://www.wsj.com/... Bryce Roberts / @bryce : Big debut for $HCAT. My Utah public portfolio continues to grow. Who's next?!? https://twitter.com/...
Context & Ripple Effects
Health Catalyst's listing caps a fast climb from private to public markets: just five months ago it closed a $100M equity-and-debt round at a $1B valuation, and today it priced above its already-raised range, sold more stock than planned, and finished its first day up 51% at roughly $1.6B.
The debut lands on the same day as Livongo's $350M+ IPO, which popped 36% to a ~$3.6B valuation — two health-data platforms pricing above boosted projections within hours of each other. That pairing matters because it follows Cardlytics' muted 2018 analytics IPO, suggesting underwriter appetite for healthcare data specifically has turned, not just tech listings generally.
First-order effects
- Health Catalyst's private backers convert at nearly a 60% markup over February's $1B round price, while co-founder-backed Utah investors like Bryce Roberts gain a flagship public holding in what he calls his Utah public portfolio.
- Livongo and Health Catalyst both sold more stock than originally expected, so both treasuries exit the window with larger war chests than their pre-roadshow plans assumed.
Second-order effects
- Venture-backed health-data companies preparing filings get a fresh pricing benchmark: a first-day pop of this size invites underwriters to keep raising ranges mid-roadshow, a pattern One Medical repeated when it closed up 58% months later.
Third-order effects
- If the pattern holds, healthcare data and chronic-care platforms become a recurring public-market category rather than opportunistic exits — a cycle later echoed by Omada Health's 2021%-style Nasdaq debut, where virtual chronic care again cleared $1B — pushing hospital systems' analytics purchasing toward listed vendors with currency for acquisitions.
The trend: Digital-health data platforms are learning to time IPOs to bursts of public-market appetite, pricing above boosted ranges and converting hot debuts into acquisition currency.